Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacqueline Corrigan-Curay

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
The New England Journal of Medicine|April 29, 2022
Real-World Evidence - Where Are We Now?John Concato, Jacqueline Corrigan-Curay
Clinical Pharmacology and Therapeutics|August 14, 2021
FDA Breakthrough Therapy Designation-Trial Design and More - CommentaryJacqueline Corrigan-Curay, Peter Stein
Clinical Pharmacology and Therapeutics|March 19, 2019
The US Food and Drug Administration's Real-World Evidence Framework: A Commitment for Engagement and Transparency on Real-World EvidenceM Khair ElZarrad, Jacqueline Corrigan-Curay
JAMA|August 15, 2018
Real-World Evidence and Real-World Data for Evaluating Drug Safety and EffectivenessJacqueline Corrigan-Curay, Leonard Sacks, Janet Woodcock
Clinical Trials (London, England)|February 18, 2018
The Clinical Trials Transformation Initiative: Looking back, looking forwardJohn H Alexander, Jacqueline Corrigan-Curay, Mark McClellan
The New England Journal of Medicine|April 12, 2018
Breakthrough-Therapy Designation - An FDA PerspectiveJacqueline Corrigan-Curay, Amy E McKee, Peter Stein
Clinical Pharmacology and Therapeutics|July 29, 2025
Evidence Generation for Drugs and Biological Products isn't Magic or MythJohn Concato, Leonard Sacks, Peter Stein, et al.
JAMA Pediatrics|July 12, 2021
Summary of Literature on Pediatric Real-world Evidence and EffectivenessAnn W McMahon, Kenneth Quinto, Amy Abernethy, et al.
Pharmacoepidemiology and Drug Safety|September 17, 2020
Randomized, observational, interventional, and real-world-What's in a name?John Concato, Peter Stein, Gerald J Dal Pan, et al.
Applied Biosafety : Journal of the American Biological Safety Association|July 11, 2015
The NIH Office of Biotechnology Activities Site Visit Program: Observations About Institutional Oversight of Recombinant and Synthetic Nucleic Acid Molecule ResearchRyan Bayha, Kathryn L Harris, Allan C Shipp, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
The New England Journal of Medicine|April 29, 2022
Real-World Evidence - Where Are We Now?John Concato, Jacqueline Corrigan-Curay
Clinical Pharmacology and Therapeutics|August 14, 2021
FDA Breakthrough Therapy Designation-Trial Design and More - CommentaryJacqueline Corrigan-Curay, Peter Stein
Clinical Pharmacology and Therapeutics|March 19, 2019
The US Food and Drug Administration's Real-World Evidence Framework: A Commitment for Engagement and Transparency on Real-World EvidenceM Khair ElZarrad, Jacqueline Corrigan-Curay
JAMA|August 15, 2018
Real-World Evidence and Real-World Data for Evaluating Drug Safety and EffectivenessJacqueline Corrigan-Curay, Leonard Sacks, Janet Woodcock
Clinical Trials (London, England)|February 18, 2018
The Clinical Trials Transformation Initiative: Looking back, looking forwardJohn H Alexander, Jacqueline Corrigan-Curay, Mark McClellan
The New England Journal of Medicine|April 12, 2018
Breakthrough-Therapy Designation - An FDA PerspectiveJacqueline Corrigan-Curay, Amy E McKee, Peter Stein
Clinical Pharmacology and Therapeutics|July 29, 2025
Evidence Generation for Drugs and Biological Products isn't Magic or MythJohn Concato, Leonard Sacks, Peter Stein, et al.
JAMA Pediatrics|July 12, 2021
Summary of Literature on Pediatric Real-world Evidence and EffectivenessAnn W McMahon, Kenneth Quinto, Amy Abernethy, et al.
Pharmacoepidemiology and Drug Safety|September 17, 2020
Randomized, observational, interventional, and real-world-What's in a name?John Concato, Peter Stein, Gerald J Dal Pan, et al.
Applied Biosafety : Journal of the American Biological Safety Association|July 11, 2015
The NIH Office of Biotechnology Activities Site Visit Program: Observations About Institutional Oversight of Recombinant and Synthetic Nucleic Acid Molecule ResearchRyan Bayha, Kathryn L Harris, Allan C Shipp, et al.
Pageof 3